Zolimomab aritox

Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus^[1] and graft-versus-host disease,^[2] but the studies failed to show positive effects of the drug.

It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).^[3]

References

^ Stafford FJ, Fleisher TA, Lee G, Brown M, Strand V, Austin HA, et al. (November 1994). "A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus". The Journal of Rheumatology. 21 (11): 2068–70. PMID 7532717.
^ Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RE (April 1994). "Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic Immunology. 1 (2): 77–82. PMID 7584486.
^ "Recommended Inn List 41 International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 13 (1): 56. 1999. Archived from the original (PDF) on February 23, 2012.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.